Valeant Pharmaceuticals International has entered an agreement to acquire Afexa Life Sciences for approximately $76 million. Afexa, a health-science company headquartered in Alberta, Canada, markets several consumer brands, such as COLD-FX and COLDSORE-FX, and has annual revenues of approximately $40 million. “We are pleased to have the full support of Afexa’s management team and board of directors for a transaction that we believe should deliver significant benefits to our customer...